2018 Endocrine Fellows Series: Type 1 Diabetes Care and Management
2018 Endocrine Fellows Series: Type 1 Diabetes Care and Management
The fifth annual Endocrine Fellows Series: Type 1 Diabetes Care and Management is a live CME-certified conference of pediatric and adult endocrine fellows held March 13-15, 2018 prior to ENDO 2018 (March 17-20, 2018) in Chicago, Illinois. Fellows attend group discussions, clinical case presentations, and networking sessions with expert faculty over the two-day program. Sessions include sick day and hospital management, insulin pumps and CGM, psychosocial factors, transitional care, and more. This year's application period is currently open. For details on the current and future programs, visit https://www.endocrine.org/meetings/fellows-conferences.
This activity is supported by a grant from the following supporters: Abbott Diabetes Care Inc.; Dexcom, Inc.; The Leona M. and Harry B. Helmsley Charitable Trust; Lilly USA, LLC; Medtronic Diabetes; Merck & Co., Inc.; Novo Nordisk Inc.
This continuing medical education activity should be of substantial interest to pediatric and adult endocrine fellows.
Upon completion of this educational activity, participants will be able to (or better able to):
- Differentially diagnose T1D in youth and assess the familial risk of developing T1D
- Utilize patient education and counseling to motivate patients and their caregivers and promote adherence
- Apply current clinical information to set appropriate blood glucose targets taking into consideration a patient’s lifestyle, age and condition
- Evaluate clinical practice guidelines on the prevention, screening and management of comorbidities
- Explain the neurological consequences of hypoglycemia and hyperglycemia and recognize potential causes
- Recognize special considerations in the management of diabetes in a trauma or in-patient setting
- Discuss the important of individualized nutrition plans and goals for patients with T1D
- Discuss the potential risks and benefits associated with emerging therapies for diabetes
Chicago-O’Hare International Airport
Distance from hotel: 18 mi.
Drive time: 35-60 min.
Directions: Follow signs for I-190 out of airport. Take I-190 to I-90/94 east (Kennedy Expressway). Take I-90/94 to Monroe Street exit, turn left on Monroe Street (East) , Approximately 8 blocks to The Palmer House Hilton. Hotel is on the right.
Chicago Midway Airport
Distance from hotel: 12 mi.
Drive time: 30-45 min.
Directions: North on Cicero Avenue. Take Stevenson Expressway (I-55) Northeast to Kennedy Expressway (I-90) West. Exit Monroe Street, turn right (East), 8 blocks to The Palmer House Hilton. Hotel is on the right.
There are a variety of parking options are available for your convenience such as overnight self parking and VIP Valet Parking. Assisted Valet Parking is also available and must be purchased in advance online with discounts for various lengths of stay. View detailed onsite parking options.
Irl B. Hirsch, MD; University of Washington Sch of Med
Linda M. Siminerio, RN, PhD, CDE; University of Pittsburgh Diabetes Institute
Roy W. Beck, MD, PhD, University of South Florida
Luisa A. Duran, MD, John Muir Health
Clark Eckel, Patient engagement participant
Jami Eckel, Patient engagement participant
Margaret Eckel, Patient engagement participant
Robert H. Eckel, MD, University of Colorado
Alison B. Evert MS, RD, CDE, University of Washington
Carla J. Greenbaum, MD, Benaroya Research Institute
James S. Hirsch, Journalist and Author
Janet B. McGill, MD, University of Washington
Elizabeth R. Seaquist, MD, University of Minnesota
Craig E. Taplin, MD, Seattle Children’s Hospital
Guillermo E. Umpierrez, MD, Emory University
Amisha Wallia, MD, Northwestern University
Jill A. Weissberg-Benchell, PhD, CDE, Northwestern University
STATEMENT OF INDEPENDENCE
As a provider of continuing medical education (CME) accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society's Special Programs Committee (SPC). The commercial supporter(s) of this activity have no influence over the planning of this CME activity.
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.
The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The following faculty reported the following relevant financial relationship(s) during the content development process for this activity:
Robert H. Eckel, MD: Consultant, Sanofi Aventis, Regeneron Pharmaceuticals; Novo Nordisk
Carla J. Greenbaum, MD: Consultant, Bristol-Myers Squibb, Pfizer, Inc.; Principal Investigator, Jansen Pharmaceuticals, Novo Nordisk
Irl B. Hirsch, MD: Consultant, Abbot Diabetes Care, Adocia, Roche, Intarcia, BigFoot; Principle Investigator, Medtronic Diabetes
Janet B. McGill, MD: Advisory Group Member, Novo Nordisk, Bayer, Intarcia; Consultant, BI/Lilly, Dexcom; Speaker, Aegerion, Dexcom, Janssen Pharmaceuticals, Mannkind, Principle Investigator, AstraZeneca/Bristol-Meyers-Squibbs, Novartis
Elizabeth R. Seaquist, MD: Advisory Group Member and Consultant, Eli Lilly & Company; Consultant, Sanofi, Zucara Therapeutics, 360 Marketing Services; Study Group Participant; Novo Nordisk
Guillermo E. Umpierrez, MD: Advisory Group Member, Sanofi, Merck & Co.; Principal Investigator, Astra Zeneca, Boehringer Ingelheim, Merck & Co., Novo Nordisk, Sanofi
Amisha Wallia, MD: Investigator, Eli Lilly; Consultant, Glytec; Trial Adjudicator, Lexicon Pharmaceuticals
The following faculty reported no relevant financial relationship: Roy W. Beck, MD, PhD; Luisa A. Duran, MD; Clark Eckel; Jami Eckel; Margaret Eckel; Alison B. Evert, MS, RD, CDE; Carla J. Greenbaum, MD; James S. Hirsch; Linda M. Siminerio, RN, PhD, CDE; Craig E. Taplin, MD; Jill A. Weissberg-Benchell, PhD, CDE.
Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.
The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the Endocrine Society.
Use of professional judgment:
The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.
Drugs and dosages:
When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.
POLICY ON UNLABELED/OFF-LABEL USE
The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.
PRIVACY AND CONFIDENTIALITY STATEMENT
The Endocrine Society will record learner's personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.
The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.
The Endocrine Society designates this live activity for a maximum of 17.25 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 17.25 AMA PRA Category 1 Credits™
- 17.25 CME Certificate of Participation